Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2025-12-31 @ 7:54 AM
Study NCT ID:
NCT02108457
Status:
COMPLETED
Last Update Posted:
2021-03-30
First Post:
2014-04-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Study Overview
Official Title:
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: